The aim of the present study was to describe the pharmacokinetics of caspofungin in 12 critically ill adult patients with suspected or proven invasive candidiasis who were receiving continuous venovenous hemodiafiltration (CVVHD).

CVVHD was performed using a polysulfone hemofilter (Fresenius, Germany). Caspofungin was administered at usual doses. Pre-filter and post-filter blood, ultradiafiltrate, and urine samples were collected at steady state on day 3 or later, before the dose infusion started, and 0.5, 1, 1.5, 2, 4, 6, 8, and 24 h after the infusion ended.

The drug concentrations were measured by high performance liquid chromatograpy (HPLC) and the following pharmacokinetic parameters were calculated: area under the concentration-time curve (AUC~0-24h~), elimination t~1/2~, volume of distribution (Vd), clearance, trough concentration (C~trough~), and maximum concentration (C~max~).

The results of our study are summarized in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}. Caspofungin was negligible in the ultradiafiltrate and urine samples, confirming the lack of drug elimination through hemofiltration or hemodialysis. Similar findings were previously described by Weiler et al. \[[@CR1]\]. Additionally, the mean concentration of caspofungin was slightly higher in the post-filter line than in the pre-filter line (Fig. [1](#Fig1){ref-type="fig"}), allowing us to rule out the adsorption to the filter hypothesized in other studies with echinocandins \[[@CR2], [@CR3]\].Table 1Individual arterial caspofungin concentrations (mg/L) of the 12 patients studiedTime (h)123456789101112Predose3.092.122.940.901.503.042.102.932.183.162.692.620.510.856.968.504.384.599.867.098.237.8111.1710.247.0219.346.198.232.804.449.116.107.236.699.918.885.781.58.555.757.05NA4.418.245.276.046.038.428.395.0927.515.476.912.433.857.374.965.885.727.747.924.6146.384.496.132.123.776.544.135.665.326.946.623.9465.633.965.63NA3.045.843.545.334.556.406.313.6085.003.405.221.992.804.713.104.454.495.616.003.27243.472.303.101.341.592.471.632.732.272.884.001.85Time refers to the time since caspofungin infusion ended. *NA* data not available Table 2Pharmacokinetics of caspofungin during continuous venovenous hemodiafiltration in 12 patientsAUC~0-24~ (mg h/L)PatientArterialVenousDifference venous to arterial (%)Vd (L)Cl (L/h)C~max~ (mg/L)C~trough~ (mg/L)t~½~ (h)1140.0180.02914.10.35612.53.4727.4288.3106.02017.10.5677.82.121.03124.0152.02310.90.4028.83.118.8465.477.41826.80.7656.91.324.3568.090.03217.50.7354.81.516.56102.0107.0513.60.68310.72.513.8765.678.82015.00.7628.31.613.68100.0113.01313.90.4999.52.719.39102.0127.02514.10.6859.22.314.310121.0142.01712.50.57812.62.915.011190.0224.01813.90.36811.54.026.21260.174.52427.71.1658.51.916.5Mean ± SD102 ± 46123 ± 4620.3 ± 7.216.4 ± 5.40.630 ± 0.2259.3 ± 2.32.4 ± 0.818.9 ± 4.9*SD* standard deviation Fig. 1Average caspofungin concentration over time. Infusion started at 0 h and continued over 1 h. *n* = 12 patients. *Solid dots*, arterial; *asterisks*, venous. (The figure is original for this article)

In four patients (33%), the trough concentration of caspofungin was lower than the MIC~90~s published for *Candida* and *Aspergillus* spp., including *Candida parapsilosis* (2 mg/L) \[[@CR4]\]. On the other hand, among echinocandins, micafungin has been associated with 1 log kill/24 h in a murine model of disseminated candidiasis when an AUC/MIC of 865, 450, or 1185 is achieved for *Candida albicans*, *Candida glabrata*, or *C. parapsilosis*, respectively \[[@CR5]\]. Taking into account a MIC of 0.1 mg/L \[[@CR4]\], and using the target pharmacokinetics/pharmacodynamics (PK/PD) described for micafungin, we would have reached this concentration in only nine patients (75%, AUC \> 86.5 mg h/L) for *C. albicans* and four patients (33%, AUC \> 118.5 mg h/L) for *C. parapsilosis* but all patients for *C. glabrata* (AUC \> 45 mg h/L) (Table [2](#Tab2){ref-type="table"}). These data suggest that caspofungin dosing could be insufficient in some critically ill patients.

In conclusion, CVVHD appears to have a negligible effect on caspofungin clearance. However, the licensed regimen of caspofungin was not adequate to reach the PK/PD targets in some critically ill patients, regardless of the use of CVVHD. Nevertheless, future studies are needed to confirm these findings.

AUC

:   Area under the concentration-time curve

C~max~

:   Maximum concentration
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